CA-GLOBAL-CRITICAL-LOGIS
1.2.2024 14:01:33 CET | Business Wire | Press release
Rock-it Cargo, a Global Critical Logistics (GCL) company and the global leader in end-to-end logistics for live events and high net worth goods, today announced the acquisition of SOS Global (SOS), the North Carolina-based freight forwarder, from NEP Group. The combined company will be the largest global specialty logistics provider in the live touring and sports and broadcast markets. The acquisition closed on January 31, 2024, and terms were not disclosed.
Rock-it’s core leadership in live music touring has been enhanced in recent years by diversifying into and significantly growing in the sports and broadcast, film and TV production, and high net worth goods sectors. Rock-it and its sister companies have offices in 18 countries and, in 2023, completed shipments in more than 115 countries. Rock-it leverages its unparalleled network and experience to deliver end-to-end solutions for its customers in every market with the same personal touch and “failure is not an option” ethos that has permeated Rock-it since its founding in 1978 with first clients Uriah Heep and Led Zeppelin.
SOS specializes in freight forwarding and logistics services for live events, particularly in the sports and broadcast industries. They service every major US sports and news broadcaster, the largest US professional sports leagues, and many of the largest vendors to these companies. Based in New Bern, NC, SOS prioritizes speed and control in its deliveries with additional offices across the United States, Canada, Germany, United Kingdom, and the United Arab Emirates.
“Today we bring together two trusted brands with a combined 83 years of experience,” said Daniel Rosenthal, President and CEO of GCL. “For 38 years, customers have known they can ‘SOS’ their most valuable goods via a 24/7/365 operational hub. SOS’s legacy will be strengthened as part of Rock-it Cargo, with expanded services and global access via our unrivaled network. I have been thrilled to get to know Ed Reno and the SOS team, and I cannot wait to grow our business and serve our customers better together. The breadth, depth and skills of Rock-it and SOS is unparalleled in global live performance touring and live sporting events.”
The acquisition aligns with GCL’s strategic plans to strengthen Rock-it’s global position within the sports and broadcast sector, as well as enhance its domestic capabilities in the live touring, events, film and theater categories. In 2023, more than 85% of GCL’s revenue was earned from international shipments, whereas a majority of SOS’s revenue was earned domestically.
Ed Reno, president of SOS, who will remain with GCL and report directly to Rosenthal, said, “Our team is very excited to combine forces with Rock-it. SOS brings a robust domestic network and operational capabilities designed to meet the needs of our sports and broadcast clients. Joining a larger international specialty logistics leader will be good for our customers and good for our team.”
GCL has made several acquisitions recently to bolster its global capabilities serving the live touring, sports, broadcast, film and TV production, fine art, and classic and high-value automobile sectors. This buying spree includes the acquisitions of Classic Automotive Relocation Services (CARS), the largest global transporter of high-value automobiles, and Dynamic International, one of the top international logistics providers for film and TV productions.
ABOUT GLOBAL CRITICAL LOGISTICS (GCL)
Headquartered in Los Angeles CA, Global Critical Logistics (GCL) is a global leader in live event entertainment logistics and high net worth logistics and freight. It is the holding company for a family of brands, including Rock-it Cargo, Dietl, Dynamic International, CARS, SOS, Cosdel, Xtreme, and Dell Will.
Focused on high-touch, mission-critical air, ocean, and surface freight forwarding and logistics services, the GCL family of leading brands work with customers across the live entertainment, music touring, sports, motor sports, corporate events, theatre, tradeshow, fine art, film and TV production, broadcast, classic and high-end automobiles, and industrial project end markets.
GCL has offices in North and South America, Europe, the Middle East, Oceania, and Asia, augmented by a network of long-term partner agents specializing in critical logistics.
The companies of GCL serve thousands of customers annually, and have provided bespoke, specialized logistics solutions for the most demanding transportation requirements across every continent for over 45 years.
GCL is backed by ATL Partners, a premier sector-focused private equity firm that invests in aerospace, transportation, and logistics and is based in New York.
For more information, please visit, gcl.global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201662351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom